Undisclosed (Targeting IAPP)
Type 2 Diabetes
Pre-clinicalActive
Key Facts
About Pangolin Therapeutics
Pangolin Therapeutics is an early-stage biotech pioneering a novel approach to drug discovery by targeting intrinsically disordered proteins (IDPs), a large class of proteins previously considered undruggable due to their lack of stable structure. The company's proprietary Pangomer platform aims to generate first-in-class therapeutics with disease-modifying potential, initially focusing on Type 2 Diabetes and neurodegeneration. Led by an experienced team and supported by $9.5M in non-dilutive funding, Pangolin is positioned to build a pipeline in high-need therapeutic areas, presenting opportunities for investment and partnership.
View full company profileTherapeutic Areas
Other Type 2 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| Diabetes Management Gel | Gelteq Limited | Formulation Development |
| Tolimidone | Biodexa Pharmaceuticals | Phase 2 |
| Generic Semaglutide Injection (Obeda) | Dr. Reddy's Laboratories | Approved |
| BioChaperone® Lispro | Adocia | Phase 3 |
| BioChaperone® Combo (Insulin Glargine / Lixisenatide) | Adocia | Phase 2 |
| Metformin API | USV Biologics Division | Commercial |
| Empagliflozin | Azico Biophore | Commercial |
| Sitagliptin Intermediate | AR Life Science | Commercial |
| AJN003 (LuCI™) | AltrixBio | Pre-clinical |
| Sitagliptin Phosphate Polymorph | Morepen Laboratories | Pre‑clinical |
| Hepatic Denervation for Type 2 Diabetes | Metavention | Feasibility |
| MVD-1 (SANA) | Eolo Pharma | Discovery |